Vitrolife completes a private share issue of sek 70 million

VITROLIFE COMPLETES A PRIVATE SHARE ISSUE OF SEK 70 MILLION Vitrolife, a leading provider of innovative products and systems for cell and tissue technologies, has completed a private share issue of SEK 70 million following an offering managed by Enskilda Securities. The shares were issued to institutional and other investors, including Ernesto Bertarelli, Chief Executive of Serono AS; world leader in reproductive health care. - We are very pleased to have raised this additional equity for investments in manufacturing capability, IT infrastructure and R&D in order to meet the increased demand for Vitrolife's products internationally, said Peter Svalander, President and CEO of Vitrolife. Vitrolife is planning for an Initial Public Offering and listing on the OM Stockholm Exchange in the spring 2001. For further information, please contact Peter Svalander, CEO of Vitrolife +46-31-721 8001 or + 46 708 228001 e-mail: Professor Lars Hamberger, Chairman of the Board + 46 31 721 8027 or + 46 708 228027 e-mail: Vitrolife is a leading Swedish Biotech Company within the area of development, production, and sales of complex solutions for assisted reproduction, cell therapy and organ transplantation. Vitrolife's products are marketed in more than 65 countries, and the company is a world leader in the area of in vitro fertilisation (IVF). For further information, please see: ------------------------------------------------------------ This information was brought to you by BIT The following files are available for download:

About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 400 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.